Log in to save to my catalogue

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer:...

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer:...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2479690224

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

About this item

Full title

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2021-01, Vol.397 (10271), p.281-292

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer.
In this double-blind, randomised, placebo-controlled, phase 2 trial, women with measurable recurrent platinum-resista...

Alternative Titles

Full title

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2479690224

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2479690224

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(20)32554-X

How to access this item